Is Anika Therapeutics, Inc. (ANIK) a Buy, Sell, or Hold?
Anika Therapeutics, Inc.
NASDAQ:ANIK
$15.52 USD
-$0.25 (-1.59%)
- Volume
- 60.04K
- Average Volume
- 90.03K
- Market Capitalization
- $206.5M
- P/E Ratio
- -19.66
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $16.49
- Year Low
- $7.87
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.46
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Stephen D. Griffin |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | ANIK |
| CUSIP | 035255108 |
| CIK | 0000898437 |
| Web | https://www.anika.com |
| Phone | 781 457 9000 |
| Currency | USD |
| Employees | 235 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.19 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.46 |
| Quick Ratio | 3.37 |
| Cash Ratio | 1.96 |
Sales & Book Value
| Annual Sales | $112.82M |
| Price / Sales | 1.78 |
| Cash Flow | 0.08 |
| Price / Cash Flow | 198.75 |
| Price / Book | 1.57 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.76 |
| Trailing P/E Ratio | -19.66 |
| PEG Ratio | -0.17 |
| P/E Growth | -0.17 |
| Net Income | $-10.88M |
| Net Margin | -9.52% |
| Pretax Margin | -8.82% |
| Return on Equity | -7.74% |
| Return on Assets | -6.17% |
Financials Score
| AltmanZ Score | 4.15 |
| Piotroski Score | 5.00 |
| Working Capital | 72.6M |
| Total Assets | 179.39M |
| Ebit | -10.26M |
| Market Cap | 209.83M |
| Total Liabilities | 45.49M |
Poll Results
About Anika Therapeutics, Inc. (NASDAQ:ANIK) Stock
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approxima ... tely 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 17:00:00
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,360 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
Bullish On Anika Therapeutics's Pullback As Integrity Scales
2026-04-30 11:21:53
Anika Therapeutics is refocusing on HA-based OA pain management and regenerative orthopedic products. The main drivers here are Monovisc, Orthovisc, and Integrity. Particularly, ANIK's Integrity received 510(k) clearance in 2023. Recently, its revenues have more than doubled in 2025. Hyalofast and Cingal also offer interesting regulatory catalysts, but they bring FDA timing and approval risks.
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
2026-04-29 11:31:42
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Anika Reports First Quarter 2026 Financial Results
2026-04-29 07:05:00
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational transformation generating early wins, delivering $4 million of adjusted EBITDA BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026.
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
2026-04-15 16:01:00
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026 financial results before the opening of the market on Wednesday, April 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
Frequently Asked Questions
-
What is the current Anika Therapeutics, Inc. (ANIK) stock price?
-
Anika Therapeutics, Inc.(NASDAQ:ANIK) stock price is $15.52 in the last trading session. During the trading session, ANIK stock reached the peak price of $16.49 while $7.87 was the lowest point it dropped to. The percentage change in ANIK stock occurred in the recent session was --1.59% while the dollar amount for the price change in ANIK stock was -$-0.25.
-
ANIK's industry and sector of operation?
-
The NASDAQ listed ANIK is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of ANIK?
-
Ben Joseph | Senior Vice President of Commercial
Ian W. McLeod | Senior VP, Chief Accounting Officer & Treasurer
Stephen D. Griffin | President, Principal Financial Officer, CEO & Director
Lisa Funiciello | VP & Chief Human Resources Officer
Matthew Hall | Executive Director of Corporate Development & Investor Relations -
How many employees does ANIK have?
-
Number of ANIK employees currently stands at 235. ANIK operates from 32 Wiggins Avenue, Bedford, MA 01730, US.
-
Link for ANIK official website?
-
Official Website of ANIK is: https://www.anika.com
-
How do I contact ANIK?
-
ANIK could be contacted at phone #781 457 9000 and can also be accessed through its website. ANIK operates from 32 Wiggins Avenue, Bedford, MA 01730, US.
-
How many shares of ANIK are traded daily?
-
The average number of ANIK shares traded daily for last 3 months was 90.03K.
-
What is the market cap of ANIK currently?
-
The market value of ANIK currently stands at $206.5M with its latest stock price at $15.52